6763-47-9

Usage

Uses

Used in Organic Synthesis:
1,2-O-Cyclohexylidene-myo-inositol is used as a key intermediate in organic synthesis for its ability to facilitate the formation of complex organic molecules. Its unique cyclohexylidene moiety allows for versatile reactions and transformations, making it a valuable asset in the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 1,2-O-Cyclohexylidene-myo-inositol is used as a building block for the development of new drugs. Its unique structure can be modified to create novel compounds with potential therapeutic applications, contributing to the advancement of medicine and healthcare.
Used in Agrochemical Industry:
1,2-O-Cyclohexylidene-myo-inositol also finds application in the agrochemical industry, where it is utilized in the synthesis of new pesticides and other crop protection agents. Its versatility in organic synthesis allows for the development of innovative and effective solutions to protect crops and enhance agricultural productivity.
Used in Specialty Chemicals:
In the specialty chemicals sector, 1,2-O-Cyclohexylidene-myo-inositol is employed as a precursor for the synthesis of various specialty chemicals. Its unique properties enable the creation of high-value products used in industries such as coatings, adhesives, and plastics, among others.

Upstream product

• 87-89-8 D-myo-inositol 
• 1122-84-5 1-ethoxycyclohexene 
• 108-94-1 cyclohexanone 
• 34361-60-9 1,2:4,5-dicyclohexylidene-myo-inositol 
• 1670-47-9 1,1-diethoxycyclohexane 
• 933-40-4 cycloxexanone dimethyl ketal 

Downstream Products

• 140840-40-0 C₂₆H₄₀O₈Si 
• 140840-40-0 C₂₆H₄₀O₈Si 
• 57029-87-5 (±)-1,2-cyclohexylidene myo-inositol 
• 6691-27-6 (+/-)-cis-1,2-O-cyclohexylidene-3,4,5,6-tetrakis-O-benzyl myo-inositol 
• 26276-99-3 rac-1,4,5,6-tetra-O-benzyl-myo-inositol 
• 148807-03-8 L-1-O-acetyl-2,3-O-cyclohexylidene-myo-inositol 
• 10583-42-3 (+/-)-1-O-allyl-3,4,5,6-tetrakis-O-benzyl myo-inositol 
• 114218-29-0 (+/-)-1-O-allyl-2,3,4,5,6-pentakis-O-benzyl myo-inositol 
• 6195-45-5 DL-2,3,4,5,6-penta-O-benzyl-myo-inositol 
• 108235-14-9 D,L-2,3,4,5,6-penta-O-benzyl-myo-inositol 1-(methanesulfonate) 
• 134275-56-2 myo-inositol 1-(-3,4-di-palmitoyloxybutyl)-sulfonate 
• 134275-56-2 myo-inositol 1-(-3,4-di-palmitoyloxybutyl)-sulfonate 
• 134275-53-9 2-(2,2-Dimethyl-[1,3]dioxolan-4-yl)-ethanesulfonic acid (1S,2R,3R,4S,5S,6R)-2,3,4,5,6-pentakis-benzyloxy-cyclohexyl ester 
• 134275-53-9 2-(2,2-Dimethyl-[1,3]dioxolan-4-yl)-ethanesulfonic acid (1S,2S,3R,4S,5S,6S)-2,3,4,5,6-pentakis-benzyloxy-cyclohexyl ester 

Relevant academic research and scientific papers

Inositol tetrakisphosphate from chicken eggshell

Unlike our previous study that identified D-myo-inositol 4,5-bisphosphate (Ins(4,5)P2, 1) from ostrich eggshell, the compound myo-inositol 1,4,5,6-tetrakisphosphate (Ins(1,4,5,6)P4, 2) was isolated as an almost racemic mixture from t

H2SO4-silica: An eco-friendly heterogeneous catalyst for the differential protection of myo-inositol hydroxyl groups

There is enormous interest in myo-inositol derivatives as they serve as precursors for the synthesis of several biologically important phosphoinositols, natural products, catalyst, supramolecular architectures etc. However the presence of six secondary hy

Efficient regioselective protection of myo-inositol via facile protecting group migration

A cis-1,2-cyclohexanediol, 1,4,5,6-tetra-O-benzyl-myo-inositol, was selectively protected at the axial C2-hydroxyl via acid-mediated rearrangement of the corresponding 1,2-orthoacetate, or via the base-induced migration of a protecting group that had previously been easily installed with complete regioselectivity at the adjacent equatorial hydroxyl. Esters 4a-6a were synthesized in high yields (75-82%) while sulfonate 7a and silyl ether 8a were obtained in 85 and 31% yields, respectively. The migration of the esters induced by DBU results in equilibrium between regioisomers favouring the C2 protected isomer, but NaH induced migration of sulfonyl and silyl groups results in complete migration from equatorial to axial hydroxyl groups.

COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS

One aspect of the present invention relates to compounds, compositions and methods for diagnosis and/or treatment of a subject suffering from an amyloidosis-associated pathological condition. In certain embodiments, the imaging and/or therapeutic agents of the instant invention may be administered to a subject for identification and/or treatment of amyloid deposits. A specific imaging method detects amyloid deposits by administering the imaging agent to the subject and detecting the spatial distribution of the agent. Differential accumulation of the agent is indicative of AD or an amyIoidosis-associated pathological condition and can be monitored by using a PET or SPECT camera.

Syntheses of penta-O-benzyl-myo-inositols, O-β-L-arabinosyl-(1 → 2)sn-myo-inositol, O-α-D-galactosyl-(1 → 3)-sn-myo-inositol, and O-α-D-galactosyl-(1 → 6)-O-α-D-galactosyl-(1 → 3)-sn-myo-inositol

Two-step conversions of myo-inositol into (±)-2,3,4,5,6- and 1,3,4,5,6-penta-O-benzyl-myo-inositols are described. Starting from these monohydroxy derivatives of myo-inositol, O-β-L-arabinopyranosyl-(1→2)-sn-myo-inositol from Japanese green tea, Camellia sinensis, and O-α-D-galactopyranosyl-(1→3)-sn-myo-inositol (galactinol) as well as its homolog, O-α-D-galactopyranosyl-(1→6(II))-galactinol, were synthesized by way of the in situ activating glycosylation procedure.

Synthesis and iron binding studies of myo-inositol 1,2,3-trisphosphate and (±)-myo-inositol 1,2-bisphosphate, and iron binding studies of all myo-inositol tetrakisphosphates

The first syntheses of the natural products myo-inositol 1,2,3-trisphosphate and (±)-myoinositol 1,2-bisphosphate are described. The protected key intermediates 4,5,6-tri-O-benzoyl-myoinositol and (±)-3,4,5,6-tetra-O-benzyl-myo-inositol were phosphorylated with dibenzyl N,N-diisopropylphosphoramidite in the presence of 1H-tetrazole and subsequent oxidation of the phosphite. The crystal structures of the synthetic intermediates (±)-1-O-(tert-butyldiphenylsilyl)-2,3-O-cyclohexylidene-myo-inositol and (±)-4,5,6-tri-O-benzoyl-1-O-(tert-butyldiphenylsilyl)-2,3-O-cyclohexy lidene-myo-inositol are reported. myo-Inositol 1,2,3-trisphosphate, (±)-myo-inositol 1,2-bisphosphate, and all isomeric myo-inositol tetrakisphosphates were evaluated for their ability to alter HO· production in the iron-catalysed Haber-Weiss reaction. The results demonstrated that a 1,2,3-grouping of phosphates in myo-inositol was necessary for inhibition, also that (±)-myo-inositol 1,2-bisphosphate potentiated HO· production. myo-Inositol 1,2,3-trisphosphate resembled myo-inositol hexakisphosphate (phytic acid) in its ability to act as a siderophore by promoting iron-uptake into Pseudomonas aeruginosa.

Synthesis of novel vitamin C phosphodiesters: Stability and antioxidant activity

A novel series of hybrid L-ascorbic acid (vitamin C) phosphodiesters linked at the C-2 hydroxyl group with other biologically active substances, namely myo-inositol, arbutin, 4-hydroxy-L-proline, and glycolic acid were synthesized, and their thermal stability and reducing activity against free radicals were estimated in vitro. All of the phosphodiesters exhibited high thermal stabilities; however, their antioxidant activities in vitro were generally lower than that of vitamin C.

Synthetic strategies based on phosphite chemistry for inositol phosphates and phospholipids

On the basis of the phosphite chemistry, new phosphorylation and glycosylation methodologies were developed. These methods were efficiently used for the syntheses of phosphatidylinositol 3,4,5-trisphosphate, and 2,6-di-O-mannopyranosylphosphatidylinositol.

Syntheses of novel hybrid vitamin C derivatives: Stability and biological activity

A novel series of hybrid L-ascorbic acid (vitamin C) derivatives linking other biologically active substances glycolic acid, myo-inositol, and α-tocopherol (vitamin E) at the C-2 or C-3 hydroxyl group were synthesized, and their thermal stability and inhibitory activities against tyrosinase-catalyzed melanin formation, active oxygen species (AOS), and free radicals were evaluated in vitro. Among these derivatives, 2-O-carboxymethylascorbic acid had high thermal stability as well as moderate inhibitory activities against tyrosinase-catalyzed melanin formation, AOS, and free radicals compared to other typical inhibitors and scavengers. On the other hand, 3-O-carboxymethylascorbic acid was markedly unstable in aqueous solution. The 2-O-carbonylmethyl derivatives linking myo-inositol or vitamin E were susceptible to degrading, however the vitamin E derivative had stronger inhibitory activities against AOS and free radicals than free vitamin C.

The First Synthesis and Iron Binding Studies of the Natural Product, myo-Inositol 1,2,3-Trisphosphate

The natural product myo-inositol 1,2,3-trisphosphate 1 has been prepared and shown to inhibit Fe3+-catalysed hydroxyl radical formation.